Table 3

Observed (Obs) and expected (Exp) number of cancers, standardised incidence ratios (SIRs) for selected cancers adjusted for age and period, and 95% CI among Navy submariners by duration of submarine service

Cancer site	ICD-10	Duration of submarine service (years)	Obs	Exp	SIR	95% CI
All sites	C00–96	≤2	440	371.24	1.19	1.08 to 1.30
All sites	C00–96	>2	342	310.07	1.10	0.99 to 1.23
Stomach	C16	≤2	11	8.71	1.26	0.63 to 2.26
Stomach	C16	>2	6	6.73	0.89	0.33 to 1.94
Colon	C18	≤2	43	29.08	1.48	1.07 to 1.99
Colon	C18	>2	25	23.31	1.07	0.69 to 1.58
Rectum, rectosigmoid	C19–20	≤2	19	17.91	1.06	0.64 to 1.66
Rectum, rectosigmoid	C19–20	>2	14	14.70	0.95	0.52 to 1.60
Pancreas	C25	≤2	4	9.13	0.44	0.12 to 1.12
Pancreas	C25	>2	8	7.50	1.07	0.46 to 2.10
Lung, trachea	C33–34	≤2	46	40.44	1.14	0.83 to 1.52
Lung, trachea	C33–34	>2	38	32.10	1.18	0.84 to 1.63
Melanoma	C43	≤2	31	20.49	1.51	1.03 to 2.15
Melanoma	C43	>2	30	18.53	1.62	1.09 to 2.31
Skin, non-melanoma	C44	≤2	29	19.88	1.46	0.98 to 2.10
Skin, non-melanoma	C44	>2	32	15.14	2.11	1.45 to 2.98
Mesothelioma	C45	≤2	4	1.73	2.31	0.63 to 5.91
Mesothelioma	C45	>2	1	1.32	0.76	0.02 to 4.22
Soft tissues	C48–49	≤2	5	1.59	3.14	1.02 to 7.32
Soft tissues	C48–49	>2	3	1.41	2.13	0.44 to 6.22
Prostate	C61	≤2	95	97.77	0.97	0.79 to 1.19
Prostate	C61	>2	81	81.65	0.99	0.79 to 1.23
Testis	C62	≤2	3	5.85	0.51	0.11 to 1.50
Testis	C62	>2	7	6.49	1.08	0.43 to 2.22
Kidney excl. renal pelvis	C64	≤2	10	11.23	0.89	0.43 to 1.64
Kidney excl. renal pelvis	C64	>2	11	9.98	1.10	0.55 to 1.97
Bladder, renal pelvis and other urinary organs	C65–68	≤2	39	25.68	1.52	1.08 to 2.08
Bladder, renal pelvis and other urinary organs	C65–68	>2	23	20.48	1.12	0.71 to 1.69
Brain, nervous system	C70–72	≤2	15	10.78	1.39	0.78 to 2.30
Brain, nervous system	C70–72	>2	6	9.91	0.61	0.22 to 1.32
Hodgkin lymphoma	C81	≤2	3	1.90	1.58	0.33 to 4.62
Hodgkin lymphoma	C81	>2	5	1.82	2.74	0.89 to 6.41
Non-Hodgkin's lymphoma	C82–86, C96	≤2	18	11.63	1.55	0.92 to 2.45
Non-Hodgkin's lymphoma	C82–86, C96	>2	9	10.20	0.88	0.40 to 1.67
Multiple myeloma	C90	≤2	4	5.44	0.73	0.20 to 1.88
Multiple myeloma	C90	>2	3	4.49	0.67	0.14 to 1.95
Leukaemia	C91–95	≤2	9	12.68	0.71	0.32 to 1.35
Leukaemia	C91–95	>2	13	10.74	1.21	0.64 to 2.07
Lymphoid/haematopoietic tissue	C81–96	≤2	37	32.60	1.13	0.80 to 1.56
Lymphoid/haematopoietic tissue	C81–96	>2	30	28.04	1.07	0.72 to 1.53
Alcohol-related cancers	*	≤2	28	17.04	1.64	1.09 to 2.38
Alcohol-related cancers	*	>2	10	14.73	0.68	0.33 to 1.25
Low-survival cancers	*	≤2	84	75.37	1.11	0.89 to 1.38
Low-survival cancers	*	>2	63	60.19	1.05	0.80 to 1.34
Non-low-survival cancers	*	≤2	356	295.87	1.20	1.08 to 1.34
Non-low-survival cancers	*	>2	279	249.88	1.12	0.99 to 1.26

Follow-up 1953–2021. Short-term service (≤2 years); n=1320, 56 402 person-years; long term service (>2 years): n=1343, 53 662 person-years.
*See footnotes in table 2.
ICD-10, International Classification of Diseases, 10th revision.